Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Parma – page 13

219 clinical trials in Parma, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Parma at a glance
219
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

219 trials in Parma

Open in trial search

Pleural mesothelioma malignant

Not recruiting

Study of Pembrolizumab with Cisplatin or Carboplatin and Pemetrexed for Patients with Resectable Malignant Pleural Mesothelioma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Istituto Oncologico Veneto

Hepatitis B virus test+1

Not recruiting

Study on the Effects of Selgantolimod and NUC Discontinuation in Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Entecavir
  • Sponsor:ANRS Maladies Infectieuses Emergentes

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan with Chemotherapy for Patients with HER2-Low, Hormone Receptor Positive Breast Cancer After Endocrine Therapy Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

HER2 positive breast cancer

Not recruiting

Study on Chemotherapy-Free Treatment with Trastuzumab, Pertuzumab, and T-DM1 for Patients with HER2-Positive Early-Stage Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Medica Scientia Innovation Research S.L.

Kidney transplant rejection

Not recruiting

Study on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Metastatic renal cell carcinoma

Not recruiting

Study on Pembrolizumab for Patients with Resectable Metastases from Kidney Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Consorzio Oncotech

Acne

Not recruiting

Study of N-Acetyl-GED-0507-34-LEVO gel 5% applied daily for treating acne vulgaris

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
  • Sponsor:PPM Services S.A.

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Early-Stage Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Philadelphia positive acute lymphocytic leukaemia

Not recruiting

Study on Ponatinib and Blinatumomab for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Extranodal marginal zone B-cell lymphoma (MALT type)

Not recruiting

Study on Chlorambucil and Rituximab for Patients with MALT Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Chlorambucil
  • Sponsor:Association International Extranodal Lymphoma Study Group (IELSG)

Acne

Not recruiting

Title: Long-term safety study of N-Acetyl-GED-0507-34-LEVO gel 5% applied to the skin for patients with acne vulgaris

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:(S)-3-(4-Acetamidophenyl)-2-Methoxypropanoic Acid
  • Sponsor:PPM Services S.A.

Cystic fibrosis

Not recruiting

Study on Thymalfasin for Adults with Cystic Fibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Thymalfasin
  • Sponsor:Sciclone Pharmaceuticals International (SG) Pte. Ltd.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Parma

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on multiple myeloma, lung cancer, and breast cancer treatments. Investigations include innovative immunotherapy approaches and targeted therapies for various cancer types.

  • Novel therapies for NSCLC patients
  • Triple-negative breast cancer treatments
  • Multiple myeloma management strategies

Research emphasizes personalized treatment approaches and combination therapies to improve patient outcomes.

02 Respiratory Medicine

Studies examining treatments for respiratory syncytial virus (RSV) infections in high-risk populations. Advanced research into preventive therapies and management strategies.

  • RSV prevention in infants
  • Respiratory support strategies
  • Critical care ventilation protocols

Focus on developing protective measures for vulnerable patient populations.

03 Transplant Medicine

Clinical trials evaluating new approaches to kidney transplantation and prevention of complications. Research on reducing delayed graft function and improving transplant outcomes.

  • Post-transplant care optimization
  • Graft function improvement
  • Novel immunosuppressive strategies

Emphasis on enhancing long-term transplant success rates.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.